The primary objective of Sirtex is to research, develop and commercialise effective treatments for liver cancer using novel small particle technology. Liver cancer is a disease of the cell. It develops when cells in a part of the body begin to grow out of control. Cancer cells can form a mass of tissue commonly referred to as a tumour.
Sirtex has developed an innovative means of treating liver cancer. In cases where it is not possible to surgically remove the liver tumours, this product can be used to deliver targeted, internal irradiation therapy directly to the tumour. This new therapy is called Selective Internal Radiation Therapy also know as SIRT.
This technology was developed in the 1980's in Perth, Western Australia. Many patients have been treated commercially and within a clinical trial setting all over the world (Australia, USA, Europe, Singapore, Hong Kong, New Zealand and India). Sirtex technology has TGA inclusion in Australia, PMA approval by the Food and Drug Administration (FDA) in the USA and BSI consent for Europe (CE Mark).
For more information on roles within this company please contact your Sirtex Account Manager